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ABSTRACT
Introduction: Despite advancement of treatment modalities, Tuberculosis (TB) treatment interruption rate has glob-
ally accelerating, calling for greater framework shifting towards psychosocial intervention. Similarly, Selangor state 
had reported the perturbing TB treatment interruption rate, which was figured persistently above 10% in the interval 
year of 2014 to 2018, thus signifies an empirical assessment on Information-Motivation-Behavioural skills (IMB) 
determinants of TB intensive phase treatment. This study aims to determine the time to intensive phase TB treatment 
interruption and its prognostic factors among newly diagnosed pulmonary Tuberculosis (PTB) smear positive patients 
in urban district Selangor.  Methods: A multi-centric prospective cohort study will recruit 695 newly diagnosed PTB 
smear positive patients at treatment centres in urban districts, Selangor. This study will utilize validated self-admin-
istered questionnaire and standardised data collection form (PROFORMA). At baseline, we will elicit information 
on IMB models constructs, additionally on socio-demographics, health service factors and clinical characteristics. 
Meanwhile, four points follow up will be executed to retrieve information on treatment status and time varying 
effects of body weight, treatment side effects, symptoms improvement and internalised stigma. Finally, survival 
analysis will be computed to identify the time to intensive phase treatment interruption and its prognostic factors. 
Conclusion: This study will enlighten IMB model determinants of intensive phase treatment interruption, hence to 
endeavour psychosocial elements in designing time relevant public health strategies in TB case management.
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INTRODUCTION
TB treatment interruption rate has increasingly recognised 
as a global public health concern. Despite advancement 
of therapeutic modalities, TB treatment interruption 
rate ranged from 10% to 30% across the developing 
countries (1-2). In the light of halting global accelerated 
TB treatment interruption, WHO has emphasized several 
strategies by means of policy and legislative framework, 
which include Directly Observed Treatment, Short-
course (DOTS) as the core policy, fee exemption policy 
for anti-TB drug in developing countries and fixed-dose 
combination tablets for TB treatment (3-4). Likewise, 
the defaulter tracing and retrieval system is distinctly 
outlined through National Tuberculosis Control Program 
in Malaysia (5). Notwithstanding rigorous measures 
targeted to optimise acceptance and access to TB 
treatment, TB treatment interruption remains as a global 
public health challenge across the nations (6-7).
World Health Organization (WHO) has characterized 
TB treatment interruption as history of stopping treatment 
for two or more consecutive months (8). Importantly, 
early treatment interruption in intensive phase has been 
emphasized in Malaysian Tuberculosis Clinical Practice 
Guideline 2012, which refers to 14 days or more of 
treatment interruption, thus warrants treatment re-start 
(9).
A large and growing body of literature has investigated 
the devastating consequences of TB treatment 
interruption. Few researchers demonstrated that non-
adherent patients took longer duration for culture 
conversion, required longer treatment regimes, and 
signified TB mortality through mechanism of treatment 
failure and drug resistance (10-11). Likewise, the 
delayed sputum conversion led to considerable amount 
of psychosocial impacts and prolonged infectiousness 
in the community (11-12). Importantly, TB treatment 
interruption significantly poses economic depletion 
through increase of hospital admission and prolonged 
course of treatment completion (13).  
In the recent years, a number of researchers delicately 
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examined the median time to TB treatment interruption 
particularly in high TB burden countries (14-17). A 
prospective cohort study involving newly diagnosed 
PTB smear-positive patients in Bandung, Indonesia 
revealed that the median time to treatment interruption 
was 36 days (14). Accordingly, previous researchers 
(15-16) reported that the median time of TB treatment 
interruption was towards the completion of the intensive 
phase during respective assessments at Kenya and West 
Africa. In contrast, a systematic review which derived 
from temporal data demonstrated that maintenance 
phase was the point of exit from treatment (17). Above 
all, it was demonstrated that poor compliance during 
intensive phase was the risk factor of unfavourable 
treatment outcome, thus pointing out the importance of 
treatment adherence during intensive phase (18).
Meanwhile, previous longitudinal studies explicitly 
highlighted those clinical factors, behavioural and health 
service factor were prognostic factors of TB treatment 
interruption.  Among them was HIV positive patients 
who had higher probability of defaulting TB treatment 
(16,19). Despite limited assessment of cognitive and 
behavioural aspect, Hill et al. (20) demonstrated that 
those who perceived the benefit of treatment had higher 
survival probability of TB treatment interruption. As 
for health service factor, it was evidenced in previous 
study that travel distance was significantly associated 
with higher rate of defaulting during maintenance phase 
mainly due to built-up cost over the time (20-21). 
In Malaysia, treatment interruption rate has been 
persistently above 4%, in the interval year of 2013 to 
2016, as compared with 2% of national target (22). 
Evidently, it depicts a significant economic burden to 
the country, as treatment interruption in Malaysia has 
required an additional annual projection of USD 5.3 
million mainly for treatment restart, prolonged course 
of treatment, prolonged hospitalization and drug 
resistance TB treatment (23). Being the most populous 
and urbanized state in Malaysia, Selangor state has 
encountered considerable challenges in implementing 
TB control strategies (24). Since 2014 to 2018, TB 
treatment interruption rate in Selangor was accelerated 
and far exceeding the 2% of national target, reported 
as 13%, 10.8%, 9.3%, 9.0% and 11.3% for respective 
year (25). 
The urbanization impacts on biomedical and 
organizational structure in health services can be 
hampered by disregarding individual psychosocial 
assessment and intervention (26). Information-
Motivation-Behavioural Skills (IMB) model was 
originally designed to conceptualize psychosocial 
determinants of HIV risk and preventive behaviour 
via three main constructs including information, 
motivation, and behavioural skills (27). Conceptually, 
individuals who are well informed, motivated to act and 
possess the prerequisite behavioural skills will likely 
to execute the positive outcome (28). Its applicability 
was empirically evidenced during assessments of TB 
treatment adherence. During the evaluation of TB 
treatment interruption in Colombia, Mateus-Solarte and 
Carvajal-Barona (29) proposed that the motivational 
factor delineated the strongest impact on treatment 
completion. Similarly, IMB Model was used to point 
the possible causal mechanisms linking the risk factors 
and TB treatment default during assessment of treatment 
adherence in Morocco, hence signified the contribution 
of each IMB model construct onto TB treatment 
interruption (30).
As one of social determinant, TB stigma has potentially 
led to negative impact on TB control through delayed 
diagnosis and high drop outs from DOTS programme 
(31). This mechanism derives from sentiment of disgrace 
and blame, which lead to self-isolation as TB-infected 
individuals internalize their community’s sceptical 
judgments about the disease (31-32). Despite numerous 
qualitative assessment of psychosocial aspect, too little 
attention has been paid for quantitative assessment of TB 
stigma impact on treatment interruption (32-33).
Therefore, this study will identify the IMB model 
determinants of intensive phase treatment interruption, 
with further conceptualization of psychosocial aspect 
particularly motivational factor. Beyond knowledge 
and attitude domain, the influence of perceived social 
support and internalised stigma on time to intensive 
phase TB treatment interruption will be empirically 
examined, hence adding value to the research gap. In 
the same boat, this study will examine the influence 
of socio-demographic, high risk behaviour, clinical 
characteristics and health service factors onto timing 
and survival probability of TB treatment interruption. 
The conceptual framework is presented in Fig. 1. 
The upsurge of TB disease burden, emerging drug 
resistance, and unfavourable treatment outcomes in 
Selangor are collectively heightened the need of local, 
psychosocial and theory based assessment of time to 
treatment interruption among newly diagnosed PTB 
smear positive patient in urban districts, Selangor. 
Therefore, this study aims to identify the time to intensive 
phase TB treatment interruption, the survival probability 
and its prognostic factors among newly diagnosed PTB 
smear positive patients in urban district Selangor. 
MATERIALS AND METHODS
Study design and study location 
Selangor state is located on the west coast of Peninsular 
Malaysia and is administratively divided into nine 
districts namely Petaling, Klang, Kuala Langat, Hulu 
Langat, Sepang, Sabak Bernam, Kuala Selangor and 
Hulu Selangor (34). Meanwhile, the urban districts in 
Selangor are those districts governed by respective 
municipal council which include Petaling, Hulu Langat, 
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Figure 1: Conceptual Framework on Biopsychosocial 
Predictors of Adolescent Aggression
that test time-to-event data (Cox Proportional Hazard, 
and equivalence), which delineated as follows;
Whereby:
Θ = hazard ratio
ln(θ) = natural logarithm of the hazard ratio, or the log-
hazard ratio (travel distance treatment centre)
pE = overall probability of the event occurring within 
the study period
pA and pB = proportions of the sample size allocated to 
the two groups, named ‘A’ and ‘B’
n   = total sample size
δ   = testing margin 
Using estimation for hazard ratio, θ of 3.0 (travel distance 
factor, estimated for study population), pE of 0.20, pA of 
0.5, pB of 0.5, δ of 0.5, power of 80%, and confidence 
interval of 95%, therefore the calculated sample size 
was 438. Finally, after adjustment for drop-out rate of 
30% and non-eligibility of 10%, the estimated sample 
size was 695. From January to June 2018, surveillance 
data (myTB) showed a total of 853 newly diagnosed 
PTB smear positive patients were started TB treatment 
in urban districts Selangor (25). Therefore, all eligible 
patients those started TB treatment during the recruitment 
period will be included in the study.
Study outcome
The outcome of interest is intensive phase treatment 
interruption. It is defined as treatment interruption for 
14 days or more, or loss to follow up (9). Besides, this 
outcome is binary variable with zero (0) is when the 
subject is censored and one (1) is when the subject has 
event occurred (intensive phase treatment interruption). 
Patients will be considered censor if (1) they have 
not experienced the event (intensive phase treatment 
interruption) at day 60 of TB treatment; or (2) died 
regardless the cause; or (3) move away or transfer to 
other treatment centre outside the study location.
Each consented patient will be followed up throughout 
the intensive phase, generally to elicit the survival times 
and the survival probability. Zero time is the date of 
starting TB treatment. Meanwhile, the end point is day 
60 of treatment day. In term of survival time, it refers 
to the days from the day one (1) of TB treatment until 
the last day of recorded treatment before treatment 
interruption occurs, or loss to follow up, or until when 
the data is censored. 
David Kleinbaum (37) denotes survival probability or 
survival function ‘is the probability that a person survives 
longer than specified time, t’. In this assessment, it reflects 
on the probability of surviving from the date of treatment 
initiation until day 60 of treatment. Hence, the survival 
probability at baseline, second, fourth, sixth, and eight 
week are referred to the percentage of patients who still 
Klang, Gombak and Sepang (34-35). For the study 
purpose, a multi-centric prospective cohort study will 
be conducted at 40 public TB Treatment Centres One 
(operationally known as Pusat Rawatan Satu [PR1]) in 
urban districts, Selangor. TB Treatment Centres One are 
government hospitals or health clinics, those function as 
centres for TB diagnosis, treatment and scheduling TB 
treatment follow up.
Study population and patient selection 
The study population consists of newly diagnosed PTB 
smear positive patients who started treatment at TB 
Treatment Centres One in urban districts, Selangor. In 
term of patient’s selection, the inclusion criteria are new 
cases of PTB smear positive, Malaysian, aged 18 years and 
above, able to understand Malay or Chinese (Mandarin) 
language, and mentally capable.   Meanwhile, patient 
with any of following criteria will be excluded from the 
study. They are TB patients who have their diagnosis 
changed to non-TB diagnosis, foreigners, multi-drug 
resistant TB patients, severely ill patients upon study 
recruitment, patients with pre-existing mental illness 
on treatment or suggestive of depressive symptoms as 
further verified by Patient Health Questionnaire (PHQ-
9) assessment, or those identified with Malay or Chinese 
(Mandarin) language barrier. 
Sample size estimation and sampling method 
Sample size was calculated based on the formula (36) 
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data obtained prior to censoring dates will be retained.
In the meantime, five appointed enumerators will 
assist on the data extraction from medical records and 
TBIS forms. A serial of training will be provided to the 
enumerators which covers on study overview, roles 
and responsibilities of enumerators, methodological 
approach including data collection skills, study 
instrument contents, and frequently asked questions 
(FAQ). 
Study measures
Upon treatment initiation, baseline assessment will be 
executed via self-administered questionnaire, which 
operationally prepared in Malay and Chinese language. 
This baseline assessment is delineated in the frameworks 
of IMB Model, with adding on evaluation of socio-
demographic factors, behavioural factors, health service 
factors and clinical characteristics. Operationally, it can 
be divided into following sections; 
Section A: Socio-demographic factors
Section A will elicit on socio-demographic factors 
including age, gender, ethnicity, marital status, 
educational level, employment status, family income, 
number of household, and type of family.
Section B: High risk behaviour
Section B will elicit on respondents’ smoking status, 
history of substance abuse and alcohol consumption, 
regardless of type or quantity.  
at treatment at baseline, week 2, week 4, week 6 and 
week 8 respectively, since the TB treatment is initiated.
Study recruitment and study procedure
The recruitment period will take place for six (6) months 
duration. During this interval period, all newly diagnosed 
PTB smear positive patients who started TB treatment at 
involving treatment centres one (PR1) will be included 
in the study. The list of patients who diagnosed with 
PTB smear positive will be retrieved on daily basis 
from TB patient registration book that is available at 
each treating centre. Therefore, all newly diagnosed 
PTB smear positive patients who presented to medical 
wards and TB clinics will be screened for eligibility. 
Upon recruitment, enumerators will discuss with site 
investigator (treating physician) whether the patient 
meets the inclusion criteria. Reasons for exclusion and 
possible refusals will be recorded. 
At baseline (upon treatment initiation), a self-
administered questionnaire is filled up by respondents 
to collect data on socio-demographic and behavioural 
factors, informational (knowledge), motivational factors 
(attitude and belief, social support, internalised stigma), 
behavioural skills factors (cue to action and self-
efficacy) and health service related factors. Meanwhile, 
clinical characteristics will be retrieved to complete a 
standardised data collection form (PROFORMA). 
Following baseline assessment, patients will be followed 
up at four (4) time points which at week 2, week 4, 
week 6, and week 8 after initiation of treatment. Apart 
from event or censoring status, time varying effect for 
symptoms improvement, anti-TB side effect, internalised 
stigma and latest recorded body weight will be elicited 
at each point of follow up. A flow chart describing the 
study procedure is demonstrated in Fig. 2. 
Data collection method 
This study will use a self-administered questionnaire 
and a standardised data collection form (PROFORMA), 
both to be applied during baseline and follow up 
assessment. PROFORMA will be used to collect data on 
co-morbidities history (chronic pulmonary obstructive 
disease, diabetes mellitus, chronic renal disease, chronic 
liver disease, HIV status and lung cancer), chest x-ray 
grading upon diagnosis, body weight and treatment 
status. These information will be abstracted from 
patient’s medical record and TBIS forms. TBIS is the TB 
disease surveillance system in Malaysia, comprises of 
32 formats on recording and reporting of TB treatment 
history and outcome (9). As for occurrence of loss to 
follow up, the ascertainment of event is conducted via 
calling of patients or next of kin. Meanwhile, if patient 
died during the course of treatment, the date of death in 
the medical record and TBIS form will be recorded as the 
date of censoring. For those who move or transfer out 
from study location, the last day of treatment will be the 
date of censoring. Among those who are censored, the 
Figure 2: Methodology Framework of Mixed Methods Study 
on Adolescent Aggression
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Section C: Symptoms assessment, traditional or 
alternative remedies and health service factors
For above purposes, this section will elicit on self-report 
of TB symptoms, alternative or traditional remedies 
practice, travel distance and waiting times spent at 
DOTS at treatment centres. In term of TB symptoms, 
it will assess on the symptoms frequency (5-points 
Likert scale ranging from 1 as never and 5 as always) 
experienced by the respondent in the past one week. 
As for alternative traditional medicine practice, it refers 
to respondents’ self-report on the practice of traditional 
healer, herbal remedies, cupping, traditional massage, 
acupuncture, Yoga, Ayurveda, homeopathy, Islamic 
practice, supplementary product or other alternative 
or traditional practice specified by the respondent. 
Those selecting one or more from listed options, will 
be considered as practicing alternative or traditional 
medicine. 
Section D: Informational factor (knowledge) 
For this section, knowledge scale is adapted from 
previous studies (38-39). It consists of 18 items, which 
operationalize general knowledge on TB treatment, 
regime and drugs utilization, specific requirement 
for compliance, potential anti-TB drug side effect or 
interaction, as well as faulty heuristic that created the 
negative decision towards adherence (27-28). The 
answer options are ‘true’, ‘false’ or ‘not sure’. Each 
question is given one (1) mark for correct answer, 
zero (0) mark for wrong or not sure. Question 19(iii), 
19(xiv), 19(xvi), 19(xvii) and 19(xviii) are the negative 
statements, therefore reverse scoring is performed. The 
total knowledge score ranging from 0 to 18. The higher 
the score indicates the better knowledge towards TB 
treatment.
Section E: Motivational factors 
In this section, it will assess the attitude and belief towards 
TB treatment, internalised stigma, and perceived social 
support.  For attitude and belief, the scale is adapted 
from previous study (39) which can be further divided 
into subscales of perceived susceptibility (5 items), 
perceived severity (5 items), perceived benefits (5 items) 
and perceived barrier (16 items). All subscales obtained 
good internal consistency in previous study (39) and will 
be rated through 4-point Likert scale (from 1 as strongly 
disagree and 4 as strongly agree). As for perceived 
susceptibility, perceived benefit  and perceived severity, 
a total score ranging from 5 to 20 for respective scale, 
whilst for perceived barrier, the total score is 16 to 
64. The higher the score indicates the higher attitude 
towards TB treatment. 
This section will also cover on internalised stigma 
evaluation using The Internalised Stigma Mental 
Illness (ISMI) scale (40). This scale had previously 
underwent adaptation and psychometric validation 
in the context of assessing stigma among TB patients 
(32). It comprises of 10 items (4-point Likert scale, from 
1 as ‘strongly disagree’ to 4 as ‘strongly agree’) which 
are conceptualized based on alienation, stereotypes 
endorsement, perceived discrimination and social 
withdrawal dimension. The total score ranging from 10 
to 40. The higher the score, indicates the higher stigma 
that perceived by the respondents.
As for social support assessment, this assessment will 
use Interpersonal Support Evaluation List shortened 
version-12 items (ISELS-S) (41). It comprises of 12 items 
(4-point Likert scale, from 0 as definitely false to 3 as 
definitely true) and evaluated on appraisal support, 
belonging support and tangible support. The total 
score for ISELS-12 ranged from 0 to 36.  The higher 
the score, the higher social support gained. In previous 
psychometric assessment, this scale was validated 
among English-and Spanish-speaking Hispanics/Latinos 
respondents from the Sociocultural Ancillary Study via 
confirmatory factor analysis which showed model fit of 
data (42). 
Section F: Behavioural skills 
Behavioural skills domain is measured via cue to action 
and self- efficacy scales. Both scales are adapted from 
previous study (38- 39). For cue to action subscale, it 
consists of 8 items (5-point Likert scale, from 1 as strongly 
disagree to 5 as strongly agree) with total score ranging 
from 8 to 40.  Meanwhile for self-efficacy subscale, 
it consists of 16 items (5-point Likert scale, from 1 as 
strongly disagree to 5 as strongly agree) with the total 
score ranges from 16 to 80. 
Section G: Clinical characteristics
This section is to retrieve information on date of starting 
treatment, history of hospitalization upon treatment 
initiation, baseline body weight, comorbidities (diabetes 
mellitus, chronic obstructive lung disease, chronic renal 
disease or chronic liver disease) and chest x-ray grading, 
mainly to be elicited from medical records and TBIS 
form. 
Upon follow up assessment, a self-administered 
questionnaire and PROFORMA will be used to evaluate 
the time varying effects of TB symptoms improvement, 
anti-TB side effects, internalised stigma and body weight, 
as well as their influence onto treatment interruption. 
Section A will cover on the TB symptoms frequency and 
anti-TB side effects. In addition, while section B will 
elicit on internalised stigma assessment. Finally, section 
C will retrieve information on the latest body weight 
and treatment status, which can be established through 
medical records and TBIS forms. 
Quality Control 
First and foremost, the questionnaire will be translated 
(forward and backward translation) in Malay and 
Chinese Language by native speakers, who are proficient 
in respective languages (43). In the meantime, an expert 
group, consists of public health physician, clinician and 
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psychologist will perform content validity assessment of 
study instruments, in regards with relevance and cultural 
equivalence of respective construct. Likewise, face 
validity will be conducted among 10 TB patients, who 
will not be included in the study, essentially to assess 
their understandings and phrasing of items. Finally, 
Exploratory Factor Analysis will be conducted among 
150 PTB smear positive patients to explore and test 
underlying dimensions of construct, as well as factors’ 
internal consistency. As for reliability assessment, 
internal consistency of pre-test questionnaire will be 
tested  using Cronbach’s alpha in IBM SPSS (Version 
25.0). In the meantime, the PROFORMA will be tested 
among 10% of estimated sample size, which is on 80 
medical records.
Data management and statistical analysis 
Data will be analysed using IBM SPSS (Version 25.0). 
Descriptive statistic of variables will be presented 
as frequency, percentage for categorical data, mean 
and standard deviation for normally distributed data, 
or median and inter-quartile range for not normally 
distributed data. Some of the independent variables will 
be re-categorized when necessary. 
Importantly, survival analysis will be computed to assess 
the relationship between explanatory  variables with the 
outcome variable. Kaplan Meier analysis will be used to 
estimate and graphically plot the survival probabilities 
using a product limit formula. As the result, the median 
survival time will be computed, and survival pattern 
for various groups can be compared. Meanwhile, the 
log-rank test will statistically compare the overall 
differences between estimated survival curves of two or 
more groups of subjects. Subsequently, univariate Cox 
proportional hazards (PH) analysis will be performed 
for all independent variables, in order to predict 
which variable that giving the prognostic significance. 
Subsequently, multivariate Cox PH regression will 
be computed to identify the independent prognostic 
variables of intensive phase treatment interruption (37). 
In considering the time varying effects exerted over 
time,  symptoms improvement, side effects occurrence, 
internalised stigma scoring and body weight change will 
be entered as the time-dependent covariates into Cox 
PH regression model. In this time dependent model, 
the covariate allows incorporation of a time interaction 
function mainly to quantify whether the predicting 
effects exerted by these variables are independent of 
time changes throughout the intensive phase of TB 
treatment. 
Ethics
This study has obtained permission and approval from 
National Medical Research and Ethics Committee 
(NMREC) of National Institute of Health, Ministry of Health 
Malaysia (Reference number:NMRR-18-1635-42371) 
and Ethic Committee for Research Involving Human 
Subject Universiti Putra Malaysia (JKEUPM). Besides, 
respondents’ consent will be executed prior to 
questionnaire distribution with additional provision of 
the information sheet explaining on study objectives 
and methodology. Meanwhile, the confidentiality of 
information will be held in strictest confidence, in which 
their names and identification information will be kept 
anonymous throughout the data analysis. 
RESULTS  
Data collection activity has been commenced and the 
findings are estimated to be published in the following 
year. The finding is expected to yield in benefits to the 
target population and the relevant authorities. First and 
foremost, this study will provide a local update on risk 
factors of intensive phase TB treatment interruption. In 
the framework of IMB model, this study will endeavour 
the empirical evidences of psychosocial factors in TB 
treatment interruption, hence to drive the integration of 
psychosocial elements in TB management.
In this assessment, the advantage of taking account on 
‘censored observations’ in survival analysis is to avoid 
an underestimation of survival probability beyond 
the fixed time-point, which may lead to undermine 
the valuable information on patients survival (44). 
Importantly, through survival analysis, this study will 
identify the time-points of intensive phase TB treatment 
interruption hence to assist the local authority and 
policy maker in planning time relevant and impactful 
adherence strategy.
DISCUSSION
The utmost importance of intensive phase in TB treatment 
is meant to render patient to non-infectious state, hence 
to curb TB transmission rate in the community (45). In 
the same boat, the relationship between TB treatment 
interruption and risk of death was higher during intensive 
phase of treatment, thus patient with intensive phase 
treatment interruption should be retrieved on priority 
basis (46). Therefore, this temporal assessment aims to 
elicit the time to intensive phase treatment interruption, 
hence prompting rigour assessment of the risk factors of 
early treatment interruption. 
While previous studies had primarily concentrated 
on biomedical aspect, psychosocial context has 
been echoed by WHO to be crucially explored in TB 
treatment interruption (6-8). Some interventions were 
not evaluated sufficiently for motivational and mediating 
factors such as comorbidities, and psychosocial aspect. 
Therefore, this assessment will be framed based on IMB 
Model in order to refine the motivational factors and to 
tailor a better understanding of psychosocial influence 
in TB treatment interruption. IMB model provides a 
relatively simple explanation for complex behaviour 
that fundamental for successful treatment adherence 
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among patients with chronic diseases (47). 
Beyond attitude and belief, this study will delineate TB 
stigma characterization among newly diagnosed PTB 
smear positive patients in urban districts, Selangor. 
Given the temporal sensitivity of stigma measurement, it 
is recommended for stigma evaluation to be conducted 
serially (48). Having said that, previous studies were 
mainly conducted in cross-sectional design whereby 
the new and old TB patients were assessed together. 
By the time of evaluation, some of the defaulters might 
not be captured as they already defaulted, giving the 
possible reason of ‘underestimate’ and non-significant 
impact of TB stigma on TB treatment interruption (49). 
Similarly, most of the investigators had only considered 
the baseline value of the covariate during previous 
assessment of body weight, TB symptoms and anti-TB 
side effect, which however failed to consider the relation 
of the survival outcome as the function of covariate 
change over time. Instead, the evaluation should be 
conducted serially as its effect on the outcome may not 
constant over the follow-up time, which can lead to 
violation of the proportional hazards assumption (50) As 
such, the time dependent model will be the best method 
to describe the data. Therefore, the prospective cohort 
design in this study will assemble newly diagnosed 
patients, through which the latter variables can be 
assessed longitudinally via five time points assessments, 
thus to elicit time varying effect on the TB treatment 
interruption. 
CONCLUSION
In parallel with biomedical evidence, this study will 
enlighten the determinants of TB treatment interruption in 
the lens of IMB model, giving emphasize on longitudinal 
psychosocial assessment, hence to gratify informed 
policy and strategy in TB treatment monitoring. 
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